BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37139989)

  • 1. Fatal cytokine-release syndrome in a patient receiving toripalimab: a case report.
    Zhou Y; Zheng GH; Li N; Liu JJ; Wang XH; Li YF
    Immunotherapy; 2023 Jun; 15(9):641-645. PubMed ID: 37139989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.
    Tay SH; Toh MMX; Thian YL; Vellayappan BA; Fairhurst AM; Chan YH; Aminkeng F; Bharwani LD; Huang Y; Mak A; Wong ASC
    Front Immunol; 2022; 13():807050. PubMed ID: 35154124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report.
    Sackstein P; Zaemes J; Kim C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
    Yomota M; Mirokuji K; Sakaguchi M; Kitahara Y; Chin F; Setoguchi K; Hosomi Y
    Intern Med; 2021 Nov; 60(21):3459-3462. PubMed ID: 33775995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine release syndrome complicated with severe rashes induced by nivolumab plus ipilimumab therapy in a patient with non-small cell lung cancer: A case report.
    Tsutsui T; Hata K; Kawaguchi M; Kobayashi H; Kakizaki Y; Miyashita Y
    Thorac Cancer; 2023 Aug; 14(23):2310-2313. PubMed ID: 37381088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
    Liu LL; Skribek M; Harmenberg U; Gerling M
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab-Induced Cytokine Release Syndrome: A Case Report and Literature Review.
    Ntwali F; Gilliaux Q; Honoré PM
    Am J Case Rep; 2024 Apr; 25():e941835. PubMed ID: 38625840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cemiplimab-induced cytokine-release syndrome: second case reported and review of the literature.
    Lhuillier M; Brière M; Artifoni M; Chapal M; Peuvrel L; Saint-Jean M
    Immunotherapy; 2023 Mar; 15(4):229-234. PubMed ID: 36789558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Ureshino H; Ando T; Kizuka H; Kusaba K; Sano H; Nishioka A; Itamura H; Shindo T; Kubota Y; Kojima K; Kimura S
    Hematol Oncol; 2018 Feb; 36(1):324-327. PubMed ID: 28971493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine release syndrome induced by immune checkpoint inhibitor treatment for uterine cervical cancer recurrence: A case report.
    Sekimata M; Kinjo Y; Tohyama A; Murakami M; Hashiwaki S; Saito Y; Higami S; Hagimoto M; Taketomi R; Hoshino K; Harada H; Ueda T; Kurita T; Matsuura Y; Yoshino K
    Oncol Lett; 2024 Jul; 28(1):331. PubMed ID: 38807673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report.
    Zhang M; Cheng Y; Hu Y; Nie L
    Thorac Cancer; 2022 May; 13(9):1419-1422. PubMed ID: 35384319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer.
    Pelster MS; Mott F; Lewin J
    Laryngoscope; 2020 Apr; 130(4):E140-E143. PubMed ID: 31074845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.
    Ciner AT; Hochster HS; August DA; Carpizo DR; Spencer KR
    Immunotherapy; 2021 Sep; 13(13):1071-1078. PubMed ID: 34287029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors.
    Ohira J; Kawamoto M; Sugino Y; Kohara N
    Medicine (Baltimore); 2020 Apr; 99(15):e19741. PubMed ID: 32282733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse edema suggestive of cytokine release syndrome in a metastatic lung carcinoma patient treated with pembrolizumab.
    Rassy EE; Assi T; Rizkallah J; Kattan J
    Immunotherapy; 2017 Mar; 9(4):309-311. PubMed ID: 28303768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
    Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
    Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete and enduring response in an elderly patient with repeated recurrent gingival squamous cell carcinoma treated by combined toripalimab and single agent chemotherapy: a case report.
    Wu Q; Zhang S; Hua X; Yu H; Zhong Y
    Ann Palliat Med; 2021 Jun; 10(6):6968-6973. PubMed ID: 33183019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies.
    Nouveau L; Buatois V; Cons L; Chatel L; Pontini G; Pleche N; Ferlin WG
    Eur J Immunol; 2021 Aug; 51(8):2074-2085. PubMed ID: 33945643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.